BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19902562)

  • 21. Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.
    Lima A; Monteiro J; Bernardes M; Sousa H; Azevedo R; Seabra V; Medeiros R
    Biomed Res Int; 2014; 2014():368681. PubMed ID: 24967362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenosine Deaminase Gene Polymorphism and Baseline Serum Level of Adenosine Deaminase as a Biomarker of Response to Methotrexate in Rheumatoid Arthritis.
    Gangadharan H; Singh A; Majumder S; Aggarwal A
    J Clin Rheumatol; 2021 Dec; 27(8):e609-e611. PubMed ID: 33044386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
    Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS
    Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.
    Nomair AM; Abdelati A; Dwedar FI; Elnemr R; Kamel YN; Nomeir HM
    Clin Rheumatol; 2024 Mar; 43(3):971-983. PubMed ID: 38311638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.
    Lima A; Seabra V; Bernardes M; Azevedo R; Sousa H; Medeiros R
    PLoS One; 2014; 9(10):e108165. PubMed ID: 25279663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.
    Malik F; Ranganathan P
    Pharmacogenomics; 2013 Feb; 14(3):305-14. PubMed ID: 23394392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
    van der Straaten RJ; Wessels JA; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Allaart CF; Bogaartz J; Tiller M; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):141-50. PubMed ID: 17286537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients.
    Muralidharan N; Sundaram R; Kodidela S; Chengappa KG; Mariaselvam CM; Misra DP; Negi VS
    Pharmacogenomics J; 2020 Apr; 20(2):342-349. PubMed ID: 31611592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis.
    Weisman MH; Furst DE; Park GS; Kremer JM; Smith KM; Wallace DJ; Caldwell JR; Dervieux T
    Arthritis Rheum; 2006 Feb; 54(2):607-12. PubMed ID: 16447238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
    Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
    Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.
    Eektimmerman F; Allaart CF; Hazes JM; Madhar MB; den Broeder AA; Fransen J; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2019 Jan; 20(2):85-93. PubMed ID: 30628539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure.
    Fransen J; Kooloos WM; Wessels JA; Huizinga TW; Guchelaar HJ; van Riel PL; Barrera P
    Pharmacogenomics; 2012 Jul; 13(9):1087-94. PubMed ID: 22838954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis.
    Chen Y; Zou K; Sun J; Yang Y; Liu G
    Pharmacogenomics; 2017 Jan; 18(2):175-195. PubMed ID: 27992285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
    Chaabane S; Marzouk S; Akrout R; Ben Hamad M; Achour Y; Rebai A; Keskes L; Fourati H; Bahloul Z; Maalej A
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):385-93. PubMed ID: 26077125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of association of ADORA
    Grk M; Milic V; Dolzan V; Maksimovic N; Damnjanovic T; Pjevic MD; Pesic M; Novakovic I; Jekic B
    Pharmacogenomics J; 2020 Dec; 20(6):784-791. PubMed ID: 32448869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
    Wessels JA; de Vries-Bouwstra JK; Heijmans BT; Slagboom PE; Goekoop-Ruiterman YP; Allaart CF; Kerstens PJ; van Zeben D; Breedveld FC; Dijkmans BA; Huizinga TW; Guchelaar HJ
    Arthritis Rheum; 2006 Apr; 54(4):1087-95. PubMed ID: 16572443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
    Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
    Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients.
    Jekic B; Lukovic L; Bunjevacki V; Milic V; Novakovic I; Damnjanovic T; Milasin J; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Kovacevic L; Krajinovic M
    Eur J Clin Pharmacol; 2013 Mar; 69(3):377-83. PubMed ID: 22763757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate.
    van Ede AE; Laan RF; De Abreu RA; Stegeman AB; van de Putte LB
    Ann Rheum Dis; 2002 Dec; 61(12):1060-4. PubMed ID: 12429535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.